

# ACL Laboratories COVID-19 and Influenza Activity Report


Updated: Oct 24, 2021



## RESPIRATORY PATHOGEN PANEL Oct 24, 2021 Positivity Rate (%)



MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Myco plasma	
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0	
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1	
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0	
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1	
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1	
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0	
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0	
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1	
OCT	0.0	0.0	0.0	0.0	0.0	0.6	7.7	8.3	0.0	1.5	1.1	0.8	0.2	0.0	0.4	0.0	0.2	21.2	1.1	4.4	0.2	0.0	0.0	
NOV																								
DEC																								

Increased prevalence of viruses: **Rhinovirus, RSV and Boca virus**



ACL RSV PCR and EIA positivity rates - trend down



# CDC Data RSV pos rate for Region 5 Chicago - (PCR – 17%↓, Antigen - 30% ↓)




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Oct 24	3.7	5.6	5.1	16.7	0	0.2	n/a	0	n/a	29.3	22.5	30.6
Oct 17	3.7	6.5	7.0	18.0	0	0	0	0	20.0	36.0	27.0	31.3
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0	22.2	31.8	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	22.9	23.5	27.0	16.7

**ACL RSV tests results are consistent with "atypical" RSV outbreak**


# ACL FLUPCR - Pos rate (%) - Oct 24, 2021



## ACL COVAG and SCVPCR - Pos rate (%) - Oct 24, 2021




# Oct 20, 2021 - daily COVID-19 cases in US - CDC





# Oct 16, 2021 – SARS-CoV-2 circulating in the US (~99.8% % Delta variants)



## US vaccination status CDC | Data as of: Oct 19, 2021

411,010,650

Vaccines Administered

219,624,445

People who received at least one dose

189,924,447

People who are fully vaccinated\*


66.2%

Percentage of the US population that has received at least one dose


57.2%

Percentage of the US population that has been fully vaccinated\*

## Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – October 16, 2021





# CDC Midwest data as of: Oct 16, 2021




2021-22 Influenza Season Week 41 ending Oct 16, 2021

ILI Activity Level



# CSF targets positivity rate is 1.3%


## ACL RMEPNL - CSF POSITIVE TARGETS - Oct 24, 2021



# The most prevalent GI bacterial target is - (Campy - 0.8%)

## ACL GPP - STOOL POS BACTERIAL TARGETS - Oct 24, 2021

- CAMPY
- CRYP
- GIARDIA
- ETEC LT/ST
- Vibrio
- E. coli 0157
- Shiga tox 2
- Shiga tox 1
- E. histo
- SALM
- SHIGA



# The most prevalent GI viral target is – (Adeno – 0.9%)

